300149 睿智医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-4.401-47.50017.503-18.3166.549
总资产报酬率 ROA (%)-2.655-28.9029.416-9.6473.918
投入资产回报率 ROIC (%)-2.971-32.38610.490-10.7354.396

边际利润分析
销售毛利率 (%)16.30224.77525.42331.69038.315
营业利润率 (%)-14.978-81.48157.553-21.02113.460
息税前利润/营业总收入 (%)-14.694-80.54857.029-16.48316.977
净利润/营业总收入 (%)-13.539-79.77528.523-23.78310.396

收益指标分析
经营活动净收益/利润总额(%)85.5557.872-11.0732.37778.224
价值变动净收益/利润总额(%)-3.5700.099186.781-3.06148.711
营业外收支净额/利润总额(%)0.5500.365-2.5191.559-3.061

偿债能力分析
流动比率 (X)1.7061.7041.7490.6941.168
速动比率 (X)1.6591.6391.6910.6251.098
资产负债率 (%)37.64239.58537.60452.83940.499
带息债务/全部投入资本 (%)9.38810.21215.47231.88731.884
股东权益/带息债务 (%)727.220654.123446.404162.182206.044
股东权益/负债合计 (%)162.846150.130164.23188.150145.454
利息保障倍数 (X)-40.073-65.38064.035-3.3844.335

营运能力分析
应收账款周转天数 (天)87.89495.71891.81476.61796.373
存货周转天数 (天)10.41614.86120.31019.26724.163